|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 欧洲机器人学的发展与未来创新显示文摘随着科学技术的飞速发展,在机器人领域涌现出许多显著的研究成果,机器人学的发展在全球范围内呈现出不尽相同的趋势,在2018世界机器人大会上,欧洲机器人协会副主席、库卡机器人有限公司德国总部研发负责人Rainer Bischoff,介绍了机器人学在欧洲的发展与未来创新。 | rainer bischoff | 2018 | 机器人产业2018，0，5： | 2 |
| 2 | Fundamental investigation in two flashover based trigger methods for low-pressure gas discharge switches显示文摘 | Marcus Iberler Rainer Bischoff Klaus Frank | 2004 | IEEE Trans on Plasma Science2004，32，1： | 1 |
| 3 | Localization in Wireless Ad-hoc Sensor Networks using Multilateration with RSSI for Logistic Applications显示文摘 | Xinwei Wang Ole Bischoff Rainer Laur Steffen Paul | 2009 | Procedia Chemistry2009，，1： | 1 |
| 4 | Hermes-an intelligent hu-manoid robot designed and tested for dependability 显示文摘 | Rainer Bischoff Volker Graefe | 2003 | Ex-perimental Robotics2003，5，： | 1 |
| 5 | Localization in wireless Ad-hoc sensor networks using multilateration with RSSI for logistic applications显示文摘 | Xin Wei Ole Bischoff Rainer Laur | 2009 | 1 ( 1 ) : 461- 4642009，1，1： | 1 |
| 6 | Localization in Wireless Ad-Hoc Sensor Networks Using Multilateration with RSSI for Logistic Applications显示文摘 | Wang Xinwei Ole Bischoff Rainer Laur | 2009 | Procedia Chemistry2009，1，： | 1 |
| 7 | Prioritization of COPD protein biomarkers,based on a systematic study of the literature显示文摘Chronic Obstructive Pulmonary Disease(COPD)is a chronic lung disease mostly due to smoking and until now diagnosed by spirometry(post bronchodilator FEV1/FVC<70%).However,in spite of the usefulness of FEV1 as diagnostic and prognostic tool,it has proven to be a weak indicator of future exacerbations,unable to predict lung function decline within COPD patients,as well as unable to identify the smokers“susceptible”to developing COPD at an early stage.Thus,there is an urgent need for biomarkers that address these questions and support clinical decision making in the diagnosis and treatment of(early)COPD.In this respect,considerable efforts have been devoted to identifying protein biomarkers that enable a better understanding of this complex disease and leading to better diagnostic and prognostic tools.However,in spite of the wide range of candidates that have been suggested as potentially useful COPD biomarkers,most remained at the level of the initial discovery,and only fibrinogen has been approved by the Food and Drug Administration(FDA)as predictor for all-cause mortality and COPD exacerbations.There is thus a need for future investigations of these biomarkers in large-scale and well characterized studies in order to prove their usefulness as surrogate endpoints.Based on this,the aim of the present review is to advance COPD biomarker development by providing a comprehensive overview of protein biomarker candidates which have been evaluated in clinical studies and prioritize them according to their potential of becoming valid,clinically useful COPD biomarkers. | Sara Ongay Frank Klont Peter Horvatovich Rainer Bischoff Nick H.T.ten Hacken | 2016 | Advances in Precision Medicine2016，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员